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Authors.Necroptosis in Nonalcoholic
SteatohepatitisFigure 1. Necroptosis is activated in human nonalcoholic
steatohepatitis (NASH) samples. Representative immunohis-
tochemical staining for phospho-MLKL on livers from different
controls (Ctl) and NASH patients. Note the speciﬁc granular
cytoplasmatic staining. See Gautheron et al3 for the speciﬁcs of
the NASH cohort as well as the technical and ethical aspects.Dear Editor:
One fundamental step along the sequence from benign
liver steatosis toward progressive steatohepatitis is the
occurrence of hepatocyte cell death, currently classiﬁed as
apoptosis. However, necroptosis, governed by the kinase
receptor-interacting protein 3 (RIP3), has emerged as an
alternative programmed cell-death pathway.1 Petra Hirsova
and Gregory J. Gores, who have made many important
contributions to the ﬁeld of cell death in the liver, published
an interesting article in Cellular and Molecular Gastroenter-
ology and Hepatology2 in which they provided a compre-
hensive overview on the role of programmed cell death
pathways in NASH. We would like to take the chance to
discuss their statement that “it is unlikely that necroptosis
contributes to liver injury and inﬂammation in NASH”
because we believe that it might be too early to exclude this
important new cell death pathway from further exploration
as a potential target in NASH patients.
The ideal model to study NASH in mice is a matter of
intensive debate. We studied the role of necroptosis in NASH
by using the model of methionine-choline-deﬁcient (MCD)
diet3 because this model was used as the experimental basis
for the investigation of the role of apoptosis in NASH, leading
even to clinical studies in NASH patients.4 We could demon-
strate that mice deﬁcient for Rip3 show a clear reduction in
MCD-diet-induced liver injury, inﬂammation, and liver
ﬁbrosis compared with wild-type mice.3 We do not know of
any other published study challenging this result in the MCD
model. In addition, this ﬁnding is consistent with a previous
study showing similar protective effects of Rip3-deletion in a
mouse model of alcoholic steatohepatitis.5 Together, these
ﬁndings suggest that necroptosis might play an important
role in the processes linking NASH with ﬁbrosis.
The authors mentioned inconsistent ﬁndings in our study
and another study on the role of caspase-8 in theMCDmodel.6
Caspase-8 represents an important upstream caspase, initi-
ating the apoptosis process downstream of death receptors
such as FAS or tumor necrosis factor (TNF).7 A newly dis-
covered function of caspase-8 is the suppression of RIP3-
dependent necroptosis through cleavage of RIP3 and
CYLD.1,4,8 Consequently, efﬁcient deletion of caspase-8
sensitizes cells to necroptosis through up-regulation of RIP3
expression. This was shown in many different experimental
settings and was the case in our studies in which we used a
well-established caspase-8 ﬂoxed line9 and the alfp-cre line
mediating robust and efﬁcient deletion of ﬂoxed genes in
parenchymal livers.3 Efﬁcient caspase-8-deletion triggered
spontaneousRIP3overexpression (as seenpreviously inmany
other organs such as gut or skin10), mild liver injury, andCellular and Molecular Gastroenterology and Hepatology 2015;1:264–2inﬂammation without any stimulation.11 Upon MCD diet
feeding, caspase-8-deﬁcient mice developed massive RIP3
elevation in hepatocytes and consequently strong liver injury
and ﬁbrosis,3 providing evidence that necroptosis is the main
cell death pathway in MCD-diet-induced NASH.
The other important study on caspase-8 in the MCD
model cited by the authors used the albumin-cre line for
deletion of Caspase-8,6 which did not lead to overexpression
of RIP3.3 Therefore, and for the fact that RIP3 knockout mice
were not used, the study by Hatting et al6 is not suitable to
speculate on the role of necroptosis in the MCD model. The
authors of the present review article mention that they have
preliminary results on a protective role of caspase-8 in a
nutritional model of hepatic steatosis (not MCD diet).2
However, in our work, caspase-8 deletion did not have any
effect in a purely nutritional NAFLD model in mice (data not
shown). A careful comparison of methodological differences
might bring further light into the controversial function of
caspase-8 in different NASH models.
Finally, in our study, we had ﬁrst shown stainings for
RIP3 in liver samples of NASH patients, exhibiting a typical
granular staining pattern in hepatocytes surrounding areas
of high lipid storage.3 Of note, Western blot analysis and
stainings for RIP3 showed a much clearer result than ex-
periments assessing the levels of the cleaved form of the
executioner caspase-3 in human NASH livers,3 suggesting
that necroptosis might be at least equally abundant in hu-
man NASH as apoptosis. It should be noted that RIP366
May 2015 Letters to the Editor 265overexpression cannot be taken as equal with execution of
necroptosis. However, we can now demonstrate that the
phosphorylated form of the protein mixed-lineage-like ki-
nase (p-MLKL), which is considered to be the executional
kinase of necroptosis,12 can be detected in human NASH
livers (Figure 1) and that it strikingly resembles the gran-
ular staining patterns of RIP3 in NASH patients.3
Independently of experimental questions in mouse
models, we believe that the activation of a known cell-death
pathway in hepatocytes in human NASH patients justiﬁes
further exploration as a pharmacologic target, potentially as
a complementary target to mediators of apoptosis.
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Aachen, GermanyFigure 1. NASH-induced liver injury is decreased in
hepatocyte-speciﬁc caspase 8 knockout mice (caspase
8Dhepa). Wild-type mice and mice carrying a hepatocyte-
speciﬁc deletion of caspase 8 were fed the FFC diet (a
NASH-inducing diet high in saturated fats, fructose, and
cholesterol) for 3 months, and serum alanine transaminase
activity was measured. P value was calculated using unpaired
two-tailed t test.References
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http://dx.doi.org/10.1016/j.jcmgh.2015.02.001Reply: We appreciate the interest and thoughtful
comments of Dr Luedde and colleagues on our
review, “Death Receptor-Mediated Cell Death andProinﬂammatory Signaling in Nonalcoholic Steatohepati-
tis.”1 As they have made several seminal insights regarding
liver pathobiology, we are ﬂattered that our perspectives on
nonalcoholic steatohepatitis (NASH), particularly on nec-
roptosis in NASH, triggered their interest. We are happy to
continue a friendly scientiﬁc dialogue.
They noted, the ideal model of NASH is a matter of
intense discussion. We highlight that animals on
methionine-choline-deﬁcient (MCD) diet lose weight andlack insulin resistance, which is in direct contrast to humans
with NASH. From our perspective, the MCD diet model is not
informative regarding the mechanisms of steatohepatitis
occurring in the context of the metabolic syndrome, and the
use of this model should be discouraged.
It is well established that cell death by necroptosis re-
quires that caspase 8 activity be inhibited or disrupted. This
requirement may challenge the biological relevance of nec-
roptosis in human liver disease. Currently, only a few con-
ditions are known that lead to disrupted caspase 8 function
in humans.2 For instance, a caspase 8 deﬁciency state
(CEDS), caused by a loss-of-function mutation in the
caspase 8 gene, is a very rare genetic disorder of the im-
mune system with no liver phenotype.3,4 Several viruses and
intracellular bacteria may express proteins interfering with
caspase 8 activation and can sensitize cells to necroptosis.5
However, this is not a feature of common hepatotropic vi-
ruses such as hepatitis C or B viruses. To date, loss of cas-
pase 8 in steatohepatitis has not been reported. Finally, in
preclinical studies of NASH, pharmacologic inhibition of
caspases have been associated with beneﬁcial effects,
including reduced hepatocyte cell death.6–8
As Dr Luedde and colleagues point out, caspase 8 dele-
tion in intestinal or skin epithelium causes receptor-
interacting serine/threonine-protein kinase 3 (RIP3)-
dependent injury in mice. Similarly, necroptosis may occur
